Measurement of protein glycation, glycated peptides, and glycation free adducts

Peritoneal Dialysis International

Volumn 25, Issue 6, 2005, Pages 522-533

  Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

3 nitrotyrosine; Glucose degradation products; Mass spectrometry; Oxidative stress; Uremia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE DEGRADATION PRODUCT; GLYCOSYLATED PROTEIN; PLASMA PROTEIN;

ARTICLE; DIALYSATE LEVEL; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; IMMUNOASSAY; KIDNEY FAILURE; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MORBIDITY; MORTALITY; NITRATION; OXIDATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TREATMENT FAILURE; UREMIA; URINARY EXCRETION;

EID: 30944457523     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500603     Document Type: Article

References (70)

1. Van Holder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934-43.
2. Thornalley PJ. Clinical significance of glycation. Clin Lab 1999; 45:263-73.
3. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16:1471-85.
4. Welten AGA, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJH. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23:213-21.
5. Thornalley PJ. Protecting the genome: defence against nucleotide glycation and emerging rote of glyoxalase I over expression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 2003; 31:1372-7.
6. Penelope Catalan M, Santamaria B, Reyero A, Ortiz A, Egido J, Ortiz A. 3,4-Di-deoxyglucosone-3-ene promotes Leukocyte apoptosis. Kidney Int 2005; 68:1303-11.
7. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
8. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
9. Amore A, Cappelli G, Cirina P, Conti G, Gambaruto C, Silvestro L, et al. Glucose degradation products increase apoptosis of human mesothelial cells. Nephrol Dial Transplant 2003; 18:677-88.
10. 1 growth arrest and induction of apoptosis. Leuk Res 1996; 20:397-405.
11. Speer O, Morkunaite-Haimi S, Liobikas J, Franck M, Hensbo L, Linder MD, et al. Rapid suppression of mitochondrial permeability transition by methylglyoxal. J Biol Chem 2003; 278:34757-63.
12. 1: amelioration by trypsin. Kidney Int 2001; 59: 53-7.
13. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003; 64:1854-66.
14. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
15. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
16. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-55.
17. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-9.
18. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375:581-92.
19. Makita Z, Radoff S, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519-22.
20. Koito W, Araki T, Horiuchi S, Nagai R. Conventional antibody against Nε-(carboxymethyl)lysine (CML) shows cross-reaction to Nε-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody. J Biochem (Tokyo) 2004; 136:831-7.
21. ε-carboxymethyllysine in milk products by a modified reversed-phase HPLC method. Food Chemistry 1999; 65: 547-53.
22. Sebekova K, Podracka L, Blazicek P, Syrova D, Heidland A, Schinzel R. Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001; 16:1105-12.
23. Wrobel K, Wrobel K, Garay-Sevilla M, Nava LE, Malacara JM. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 1997; 43:1563-9.
24. Thomas MC, Tsalamandris C, MacIsaac R, Medley T, Kingwell B, Cooper ME, et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004; 66:1167-72.
25. Buxton T, Guilbault GG. Fluorometric analysis for N′-formylkynurenine in plasma and urine. Clin Chem 1974; 20: 765-8.
26. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41:153-9.
27. Wilker SC, Chellan P, Arnold BM, Nagaraj RH. Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins. Anal Biochem 2001; 290:353-8.
28. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation endproducts. J Biol Chem 2000; 275:39027-31.
29. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Nε-carboxymethyl-lysine- and Nε-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002; 364: 1-14.
30. Dobler D, Ahmed N, Thornalley PJ. Peptide mapping of type IV collagen modified minimally by methylglyoxal in vitro. Ann N Y Acad Sci 2004; 1043:906.
31. Odani H, Matsumoto Y, Shinzato T, Usami J, Maeda K. Mass spectrometric study on the protein chemical modification of uremic patients in advanced Maillard reaction. J Chromatogr B Biomed Sci Appl 1999; 731:131-40.
32. Teerlink T, Barto R, ten Brink HJ, Schalkwijk CG. Measurement of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl) lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50: 1222-8.
33. Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebekova K, Schinzel R, et al. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 2004; 41:913-19.
34. Ivanov VT, Karelin AA, Blishchenko EY, Philippova MM, Nazimov IV. Proteolytic degradation of hemoglobin in vivo. Role in formation of tissue specific peptide pool. Pure Appl Chem 1998; 70:67-74.
35. Gai M, Cantaluppi V, Fenocchio C, Motta D, Masini S, Pacitti A, et al. Presence of protein fragments in urine of critically ill patients with acute renal failure: a nephrologic enigma. Clin Chem 2004; 50:1822-4.
36. Friedlander MA, Wu YW, Elgawish A, Monnier VM. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 1996; 97:728-35.
37. Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov OK, Dawnay A. Mass spectrometric monitoring of albumin in uremia. Kidney Int 2000; 58:2228-34.
38. Ahmed N, Dobler D, Dean M, Thornalley PJ. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005; 280:5724-32.
39. Agalou S, Karachalias N, Tucker B, Thornalley PJ, Dawnay A. Estimation of α-oxoaldehydes formed from the degradation of glycolytic intermediates and glucose fragmentation in blood plasma of human subjects with uraemia. Int Congr Ser 2002; 1245:182.
40. Mann VM, Tucker B, Thornalley PJ, Dawnay A. Elevated plasma methylglyoxal and glyoxal in uremia: implications for advanced glycation endproduct formation. Kidney Int 1999; 55:2582.
41. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 1999; 256:89-93.
42. Wieslander A, Linden T, Musi B, Jarkelid L, Speidel R, Beck W, et al. Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. Contrib Nephrol 2001; 131:82-9.
43. Odani H, Iijima K, Nakata M, Miyata S, Kusunoki H, Yasuda Y, et al. Identification of Nω-carboxymethylarginine, a new advanced glycation endproduct in serum proteins of diabetic patients: possibly a new marker of aging and diabetes. Biochem Biophys Res Commun 2001; 285:1232-6.
44. Ahmed MU, Thorpe SR, Baynes JW. Identification of Nε-carboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261:4889-94.
45. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-16.
46. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271:9982-6.
47. ε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-13.
48. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ. High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 2004; 47:2235-46.
49. Ahmed N, Babaei-Jadidi R, Karachalias N, Thornalley PJ. Degradation products of proteins damaged by glycation and oxidation increase markedly in experimental diabetes and are suppressed by high dose therapy with thiamine and Benfotiamine [Abstract]. Diabetologia 2005; 48(Suppl 1): A417.
50. Drinda S, Franke S, Canet CC, Petrow P, Brauer R, Huttich C, et al. Identification of the advanced glycation end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 488-92.
51. Rippe B, Stelin G, Haraldsson B. Computer-simulations of peritoneal-fluid transport in CAPD. Kidney Int 1991; 40: 315-25.
52. Park MS, Heimburger O, Bergstrom J, Waniewski J, Werynski A, Lindholm B. Peritoneal transport during dialysis with amino acid-based solutions. Perit Dial Int 1993; 13:280-8.
53. Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Squifflet JP, et al. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol Heart Circ Physiol 1998; 275: H234-H242.
54. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003; 83:183-252.
55. de La Motte S, Plum J, Passlick-Deetjen J, Grabensee B. One-compartment model for amino acids and other biological molecules in peritoneal dialysis. Int J Clin Pharmacol Ther 2002; 40:60-8.
56. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer GA, Munch G. Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2004; 92:255-63.
57. Amajuoyi IK, Ahmed N, Watts R, Thornalley PJ. High Levels of free advanced glycation endproducts in synovial fluid in arthritis. Biochem Soc Trans 2003;. http://www.biochemistry.org/meetings/abstracts/679/6790g23.pdf
58. Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-Associated Arthropathy. Rheumatology 1992; 31:157-62.
59. Chalmers A, Reynolds WJ, Oreopoulos DG, Meema HE, Meindok H, deVeber GA. The arthropathy of maintenance intermittent peritoneal dialysis. CMAJ 1980; 123:635-8.
60. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998; 9:2368-76.
61. Thornalley PJ. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003; 31:1343-8.
62. Suzuki K, Koh YH, Mizuno H, Hamaoko R, Taniguchi N. Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone. J Biochem 1998; 123:353-7.
63. Izaguirre G, Kikonyogo A, Pietruszko R. Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties among the three isozymes. Comp Biochem Physiol Biochem Mol Biol 1998; 119:747-54.
64. Szwergold BS, Howell S, Beisswenger PJ. Human fructosamine-3-kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001; 50:2139-47.
65. Collard F, Wiame E, Bergans N, Fortpied J, Vertommen D, Vanstapel F, et al. Fructosamine 3-kinase-related protein and deglycation in human erythrocytes. Biochem J 2004; 382:137-43.
66. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003; 31:1343-8.
67. Michalek MT, Grant EP, Rock KL. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. J Immunol 1996; 157:617-24.
68. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 1998; 44:1013-23.
69. Thornalley PJ. Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diabetes and Vascular Disease Research 2004; 1:21-2.
70. Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 2001; 44:433-6.